Elvitaal B-STRESS Complex (2020.)
Food supplement registered in Latvia
Register snapshot dated 2 May 2025. It does not establish the current status of the product.
- Number published by PVD
- 0000175/2020
- Type
- Food supplement
- Published status
- Status not provided in this export; the validity date is shown separately
- Licence holder
- SIA ''Mani Vitamīni''
- Manufacturer
- name not reproduced (no recognised company form)
- Origin
- Latvija
- Register snapshot
- 2 May 2025
- Recommended daily intake (Latvian text)
- 1 tablete dienā
- Published pack size
- tabletes pa 922 mg
- Published packaging
- 90 vai 180 tabletes
This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.
The foreign register category does not determine the regulatory category of the product in France.
Published composition
| Published name | Published text and quantity | Recognised ingredient | Role or context |
|---|---|---|---|
| B1 VITAMĪNS | vitamins ; B1 VITAMĪNS ; 25 ; mg | Vitamine B1 (thiamine) | Vitamin or mineral |
| B2 VITAMĪNS | vitamins ; B2 VITAMĪNS ; 25 ; mg | Vitamine B2 (riboflavine) | Vitamin or mineral |
| NIACĪNS | vitamins ; NIACĪNS ; 20 ; mg NE | Vitamine B3 (niacine) | Vitamin or mineral |
| PANTOTĒNSKĀBE | vitamins ; PANTOTĒNSKĀBE ; 20 ; mg | Acide pantothénique (vitamine B5) | Vitamin or mineral |
| B6 VITAMĪNS | vitamins ; B6 VITAMĪNS ; 10 ; mg | Vitamine B6 | Vitamin or mineral |
| B12 VITAMĪNS | vitamins ; B12 VITAMĪNS ; 20 ; μg | Vitamine B12 | Vitamin or mineral |
| FOLSKĀBE | vitamins ; FOLSKĀBE ; 30 ; μg | Folates (vitamine B9) | Vitamin or mineral |
| BIOTĪNS | vitamins ; BIOTĪNS ; 20 ; μg | Biotine (vitamine B8) | Vitamin or mineral |
| Kalcijs | minerals ; Kalcijs ; 25 ; mg | Calcium | Vitamin or mineral |
| Magnijs | minerals ; Magnijs ; 75 ; mg | Magnésium | Vitamin or mineral |
| Apiņu augļkopu pulveris | plants ; Apiņu augļkopu pulveris ; Humulus lupulus ; 25 ; mg | humulus lupulus | Plant |
| Pasifloras lakstu pulveris | plants ; Pasifloras lakstu pulveris ; Passiflora incarnata ; 25 ; mg | passiflora incarnata | Plant |
| Kalifornijas magones virszemes daļas pulveris | plants ; Kalifornijas magones virszemes daļas pulveris ; Eschscholtzia californica ; 25 ; mg | Not recognised | Role not identified |
| Baldriāna saknes ekstrakts 4:1 | plants ; Baldriāna saknes ekstrakts 4:1 ; Valerianae officinalis ; 25 ; mg | Not recognised | Role not identified |
| Mikrokristāliskā celuloze (E460i) | otherIngredients ; Mikrokristāliskā celuloze (E460i) | Not recognised | Role not identified |
| Paraaminobenzoiskābe | otherIngredients ; Paraaminobenzoiskābe ; 20 ; mg | Not recognised | Role not identified |
| Holīns | otherIngredients ; Holīns ; 20 ; mg | Not recognised | Role not identified |
| Inozīts | otherIngredients ; Inozīts ; 20 ; mg | Not recognised | Role not identified |
| Taukskābju magnija sāļi (E470b) | otherIngredients ; Taukskābju magnija sāļi (E470b) | Not recognised | Role not identified |
| Silīcija dioksīds (E551) | otherIngredients ; Silīcija dioksīds (E551) | Not recognised | Role not identified |
Quantities are reproduced as published. The export does not specify their basis: the recommended daily intake cannot be used to calculate a daily dose. No daily dose is estimated. Latvian names are retained without translation.
Manufacturer countries
Nīderlande
French and European references for recognised ingredients
- Information
Amount read: 75 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
French reference: maximum dose of 300 mg a day (Order of 9 May 2006, not revised since November 2006).
French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Information
EFSAEuropean Food Safety Authority. reference for adults: 250 mg a day, food included (safety limit).
EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
- Information
Amount read: 25 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
humulus lupulus is not on the plant list of the Order of 24 June 2014: this is not a prohibition (a product legally sold in another Union country may contain it).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
passiflora incarnata is not on the plant list of the Order of 24 June 2014: this is not a prohibition (a product legally sold in another Union country may contain it).
French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
Amount read: 20 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Amount read: 20 mg NE. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Vitamin B3 with no form specified: the maximum dose in France is 54 mg for nicotinamide and 8 mg for nicotinic acid; the form is on the label.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Amount read: 10 mg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
French reference: maximum dose of 2 mg a day (Order of 9 May 2006, not revised since November 2006).
French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Information
EFSA reference for adults: 12 mg a day, food included (safety limit).
EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
- Information
Amount read: 20 µg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
Amount read: 30 µg. Daily basis unknown: no comparison with daily reference values.
PVD, Latvian food supplement register, retrieved 28 October 2026.
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
- Information
French reference: maximum dose of 200 µg a day (Order of 9 May 2006, not revised since November 2006).
French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Information
EFSA reference for adults: 1,000 µg a day, food included (safety limit).
EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
- Information
French reference: maximum dose of 800 mg a day (Order of 9 May 2006, not revised since November 2006).
French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Information
EFSA reference for adults: 2,500 mg a day, food included (safety limit).
EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
Unrecognised ingredients are not assessed. The absence of a signal does not establish product compliance.
Official source
Internet Archive copy dated 3 May 2025
PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Apiņu augļkopu pulveris
Read the warning, when it applies and the studies cited
HOPS - HUMULUS LUPULUS
Route of administration: Oral
Cautions and warnings
Condition of application: Sleep aid.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (Berardi et al. 2002; Dipiro et al. 2002).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Other uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Mills and Bone 2005; McGuffin et al. 1997).
4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid taking with alcohol or products that cause drowsiness (Brinker 2010).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product exercise caution if you drive or use machinery as this product may cause drowsiness (EMA 2014).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
- Pasifloras lakstu pulveris
Read the warning, when it applies and the studies cited
PASSIONFLOWER -PASSIFLORA INCARNATA
Route of administration: Oral
Cautions and warnings
Condition of application: Sleep aid.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists for more than 4 weeks (chronic insomnia) (Berardi et al. 2002: DiPiro et al. 2002).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2014).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid taking with alcohol or products that cause drowsiness (EMA 2014; Brinker 2010).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2014).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (EMA 2014).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.